Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2008-10-30 Regulatory Filings
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is dated October 30, 2008, and contains a headline announcing successful Phase IIb study results for a drug called eprotirome regarding the treatment of high blood lipids. It details clinical trial outcomes (LDL cholesterol reduction, safety profile) and includes quotes from the CEO discussing robust data and plans for Phase III studies and partner discussions. This content structure—announcing significant clinical trial results and providing context on the drug's potential and market—is characteristic of an Earnings Release (ER) or a specific clinical/scientific update. Since it focuses purely on the results of a specific study and its implications, rather than a broad overview of all quarterly performance (which would be an IR or MDA), it fits best as an initial announcement of key financial/development results. Given the options, 'ER' (Earnings Release) is the closest fit for a major, period-specific announcement of positive results, although it is technically a clinical trial update. However, since it is a press release announcing key development milestones and results, and not a formal regulatory filing like a 10-K or IR, 'ER' is the most appropriate classification for a major periodic announcement of performance/results.
2008-10-30 Swedish
Earnings Release 2008
Earnings Release Classification · 95% confidence The document is dated October 30, 2008, and presents 'Top line data' and results from a 'phase IIb study' regarding the drug eprotirome. It details clinical findings, safety profiles, and market opportunities. This structure—announcing specific clinical trial results and providing context about the drug and market—is characteristic of an Earnings Release (ER) or a press release announcing significant operational/clinical milestones. Since it is not a full annual report (10-K), a comprehensive quarterly report (IR), a transcript (CT), or a formal regulatory filing announcement (RPA/RNS), the most appropriate classification for a press release focused on financial/operational performance highlights (Phase II results) is Earnings Release (ER). The length (6219 chars) is substantial enough to contain key highlights rather than just a link to a report. FY 2008
2008-10-30 English
Interim / Quarterly Report 2008
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT JANUARI-SEPTEMBER 2008' (Interim Report January-September 2008). It contains comprehensive financial statements, including income statements, cash flow data, and balance sheet summaries for the nine-month period. It also includes detailed management commentary on business operations, R&D projects, and financial performance. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2008
2008-10-23 Swedish
Interim / Quarterly Report 2008
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY–SEPTEMBER 2008' and contains comprehensive financial statements, including net sales, operating expenses, profit/loss, cash flow, and balance sheet data for the nine-month period. It also includes management commentary, project portfolio updates, and significant events. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2008
2008-10-23 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a press release announcing the extension of a collaboration agreement between Karo Bio and Wyeth regarding drug development for atherosclerosis. It details the purpose of the extension, quotes the CEO, provides scientific background on the target protein (LXR), and includes contact information and company background. This type of announcement, which is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR), but rather a general corporate update about business operations and partnerships, fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous regulatory announcement, or potentially 'LTR' if it were a legal proceeding, but here it is a business development. Given the options, RNS serves as the best general catch-all for non-standard, non-financial-specific corporate news releases that are still publicly disseminated. It is too specific for RNS if 'TAR' (M&A Activity) were applicable, but this is a collaboration extension, not a merger or takeover. Therefore, RNS is the most appropriate general classification for this corporate news release.
2008-08-14 Swedish
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a press release announcing the extension of a research collaboration between Karo Bio and Wyeth regarding atherosclerosis treatment. It details the scientific background, the extension terms (until August 31, 2009), and provides contact information. This type of announcement, which details strategic business developments, partnerships, or significant operational updates outside of routine financial reporting (like earnings or annual reports), fits best under the general category of Regulatory Filings (RNS) or potentially a specific strategic update if one were available. Since there is no specific category for 'Collaboration Announcement' and it is not a standard financial report (10-K, IR, ER), nor is it about management changes (MANG), director trades (DIRS), or capital structure (CAP), RNS serves as the most appropriate general regulatory announcement category. The document length (3079 chars) is short, but it is the primary content, not an announcement *of* another report.
2008-08-14 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.